[CMV-CTL for treatment of refractory CMV infection in 17 patients following alternative donor hematopoietic stem cell transplantation].
作者信息
Gui R R, Li Z, Zu Y L, Wang J, Liu Y Y, Zhang B L, Yu F K, Zhang Yanli, Zhao H F, Wang P, Song Y P, Zhou J
机构信息
Department of Hematology, Affiliated Cancer Hospital Zhengzhou University, Henan Tumor Hospital, Zhengzhou 450008, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2021 Oct 14;42(10):865-868. doi: 10.3760/cma.j.issn.0253-2727.2021.10.013.
Abstract
摘要
相似文献
1
[CMV-CTL for treatment of refractory CMV infection in 17 patients following alternative donor hematopoietic stem cell transplantation].[巨细胞病毒特异性细胞毒性T淋巴细胞用于治疗17例接受替代供体造血干细胞移植后难治性巨细胞病毒感染]
Zhonghua Xue Ye Xue Za Zhi. 2021 Oct 14;42(10):865-868. doi: 10.3760/cma.j.issn.0253-2727.2021.10.013.
2
3
Protective immunity transferred by infusion of cytomegalovirus-specific CD8(+) T cells within donor grafts: its associations with cytomegalovirus reactivation following unmanipulated allogeneic hematopoietic stem cell transplantation.供者移植物内输注巨细胞病毒特异性 CD8(+) T 细胞所介导的保护性免疫：与未处理的异基因造血干细胞移植后巨细胞病毒再激活的关系。
Biol Blood Marrow Transplant. 2010 Jul;16(7):994-1004. doi: 10.1016/j.bbmt.2010.02.007. Epub 2010 Feb 16.
4
Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation.四聚体监测以评估异基因造血干细胞移植后巨细胞病毒复发的危险因素及抗病毒免疫重建情况。
Transpl Infect Dis. 2011 Jun;13(3):222-36. doi: 10.1111/j.1399-3062.2011.00626.x. Epub 2011 May 18.
5
Expansion of recipient-derived antiviral T cells may influence donor chimerism after allogeneic stem cell transplantation.受体来源的抗病毒T细胞的扩增可能会影响异基因干细胞移植后的供体嵌合状态。
Transpl Infect Dis. 2013 Dec;15(6):627-33. doi: 10.1111/tid.12101. Epub 2013 Jun 19.
6
Patients with refractory cytomegalovirus (CMV) infection following allogeneic haematopoietic stem cell transplantation are at high risk for CMV disease and non-relapse mortality.异基因造血干细胞移植后难治性巨细胞病毒（CMV）感染的患者存在 CMV 疾病和非复发死亡率高的风险。
Clin Microbiol Infect. 2015 Dec;21(12):1121.e9-15. doi: 10.1016/j.cmi.2015.06.009. Epub 2015 Jun 17.
7
Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation.异基因干细胞移植后巨细胞病毒特异性T细胞重建的直接可视化。
Blood. 2001 Mar 1;97(5):1232-40. doi: 10.1182/blood.v97.5.1232.
8
Treatment of refractory CMV-infection following hematopoietic stem cell transplantation with the combination of foscarnet and leflunomide.造血干细胞移植后难治性巨细胞病毒感染采用膦甲酸钠与来氟米特联合治疗。
Klin Padiatr. 2006 May-Jun;218(3):180-4. doi: 10.1055/s-2006-933412.
9
Donor CMV-specific cytotoxic T lymphocytes successfully treated drug-resistant cytomegalovirus encephalitis after allogeneic hematopoietic stem cell transplantation.供体巨细胞病毒特异性细胞毒性T淋巴细胞成功治疗异基因造血干细胞移植后的耐药性巨细胞病毒脑炎。
Hematology. 2020 Dec;25(1):43-47. doi: 10.1080/16078454.2019.1710945.
10
Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.异基因造血干细胞移植后巨细胞病毒再激活与移植后存活至第100天的急性髓系白血病患者复发风险降低相关：日本造血细胞移植学会移植相关并发症工作组
Biol Blood Marrow Transplant. 2015 Nov;21(11):2008-16. doi: 10.1016/j.bbmt.2015.07.019. Epub 2015 Jul 26.
引用本文的文献
1
[Refractory or resistant cytomegalovirus infections after hematopoietic stem cell transplantation: diagnosis and management].造血干细胞移植后难治性或耐药性巨细胞病毒感染：诊断与管理
Zhonghua Xue Ye Xue Za Zhi. 2024 Nov 14;45(11):1058-1064. doi: 10.3760/cma.j.cn121090-20240615-00223.
2
Refractory cytomegalovirus infections in Chinese patients receiving allogeneic hematopoietic cell transplantation: a review of the literature.异体造血细胞移植后中国患者难治性巨细胞病毒感染：文献复习。
Front Immunol. 2023 Dec 22;14:1287456. doi: 10.3389/fimmu.2023.1287456. eCollection 2023.
本文引用的文献
1
First-line Therapy With Donor-derived Human Cytomegalovirus (HCMV)-specific T Cells Reduces Persistent HCMV Infection by Promoting Antiviral Immunity After Allogenic Stem Cell Transplantation.供体源性人巨细胞病毒（HCMV）特异性 T 细胞的一线治疗可通过促进异基因干细胞移植后抗病毒免疫来减少持续性 HCMV 感染。
Clin Infect Dis. 2020 Mar 17;70(7):1429-1437. doi: 10.1093/cid/ciz368.
2
Rapid reconstitution of CMV-specific T-cells after stem-cell transplantation.干细胞移植后巨细胞病毒特异性 T 细胞的快速重建。
Eur J Haematol. 2018 Jul;101(1):38-47. doi: 10.1111/ejh.13077. Epub 2018 May 17.
3
Cytomegalovirus-Specific T-Cell Transfer for Refractory Cytomegalovirus Infection After Haploidentical Stem Cell Transplantation: The Quantitative and Qualitative Immune Recovery for Cytomegalovirus.单倍体相合干细胞移植后难治性巨细胞病毒感染的巨细胞病毒特异性T细胞转移：巨细胞病毒的定量和定性免疫恢复
J Infect Dis. 2017 Nov 15;216(8):945-956. doi: 10.1093/infdis/jix357.
4
Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.从干细胞或第三方供体中转移最小化处理的 CMV 特异性 T 细胞，以治疗 allo-HSCT 后 CMV 感染。
Leukemia. 2017 Oct;31(10):2161-2171. doi: 10.1038/leu.2017.16. Epub 2017 Jan 16.
5
Alternative Donor Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Refractory Severe Aplastic Anemia.采用大剂量移植后环磷酰胺的替代供体移植治疗难治性重型再生障碍性贫血
Biol Blood Marrow Transplant. 2017 Mar;23(3):498-504. doi: 10.1016/j.bbmt.2016.12.628. Epub 2016 Dec 21.
6
CMV in Hematopoietic Stem Cell Transplantation.造血干细胞移植中的巨细胞病毒
Mediterr J Hematol Infect Dis. 2016 Jun 20;8(1):e2016031. doi: 10.4084/MJHID.2016.031. eCollection 2016.
7
Risk factors and prognostic scale for cytomegalovirus (CMV) infection in CMV-seropositive patients after allogeneic hematopoietic cell transplantation.异基因造血细胞移植后巨细胞病毒（CMV）血清学阳性患者CMV感染的危险因素及预后量表
Transpl Infect Dis. 2015 Aug;17(4):510-7. doi: 10.1111/tid.12398. Epub 2015 Jun 18.
8
Clinical impact of neutropenia related with the preemptive therapy of CMV infection in solid organ transplant recipients.中性粒细胞减少与实体器官移植受者 CMV 感染抢先治疗相关的临床影响。
J Infect. 2014 Nov;69(5):500-6. doi: 10.1016/j.jinf.2014.07.001. Epub 2014 Jul 16.
9
[Prevention or treatment CMV infections after allogeneic hematopoietic stem cell transplant by cytomegalovirus specific T cells].[通过巨细胞病毒特异性T细胞预防或治疗异基因造血干细胞移植后的巨细胞病毒感染]
Zhonghua Xue Ye Xue Za Zhi. 2013 Mar;34(3):269-72. doi: 10.3760/cma.j.issn.0253-2727.2013.03.022.
10
Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation.供者来源的 CMV 特异性 T 细胞减少了异基因干细胞移植后 CMV 靶向药物治疗的需求。
Blood. 2013 May 2;121(18):3745-58. doi: 10.1182/blood-2012-08-448977. Epub 2013 Feb 22.
Zotero 插件